Dabur India updates on Q1 FY25
Dabur's consolidated revenue is expected to register mid to high single digit growth during Q1 FY25
Dabur's consolidated revenue is expected to register mid to high single digit growth during Q1 FY25
Vabysmo PFS is the first and only syringe prefilled with an FDA-approved bispecific antibody to treat retinal conditions that can cause blindness
Aim of the collaboration is to develop mRNA platform technology, scale up and troubleshoot challenges in mRNA process optimization
The initiative aims to empower individuals to take proactive steps towards monitoring their health
The initiative aimed to reach and support individuals suffering from epilepsy through early detection and effective disease management
Submission based on positive SUPERNOVA Phase III trial data which demonstrated a statistically significant reduction in the incidence of COVID?19 in an immunocompromised patient population
Ibara will drive AI-powered clinical research innovation
DKSH’s Business Unit Consumer Goods further capitalizes on its position to strengthen the consumer health, nutrition, and baby care categories
Offering testing, treatment and support to help stop the spread of HIV and other infectious diseases
The launch of Cefepime-Enmetazobactam marks a significant milestone for India's pharmaceutical industry in fight against AMR
Subscribe To Our Newsletter & Stay Updated